Vancouver-based psychedelic biotechnology company Bright Minds Biosciences announced a non-brokered private placement to raise CAD 0.9 million. The placement comprises 0.67 company units at CAD 1.36 per unit. The company's CEO and director, Ian McDonald, subscribed to the entire offering.
The funds raised will be used toward the company's Phase II clinical trial for BMB-101 in a pediatric epilepsy indication.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.